Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Charleroi – page 89

1 305 clinical trials in Charleroi, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Charleroi at a glance
1 305
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 305 trials in Charleroi

Open in trial search

Heart failure with preserved ejection fraction

Not recruiting

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Preserved Ejection Fraction

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Adenocarcinoma gastric+1

Not recruiting

Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Hidradenitis

Not recruiting

Study on Long-Term Use of Spesolimab for Patients with Hidradenitis Suppurativa Who Completed a Previous Spesolimab Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Small cell lung cancer limited stage

Not recruiting

Study of Tarlatamab for Patients with Limited-Stage Small-Cell Lung Cancer After Chemoradiotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Amgen Inc.

Marginal zone lymphoma

Not recruiting

Study of Ibrutinib and Rituximab for Patients with Untreated Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Small cell lung cancer extensive stage

Not recruiting

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atigotatug
  • Sponsor:Bristol Myers Squibb International Corporation

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Non-small cell lung cancer

Not recruiting

Study of Durvalumab with Radiation Therapy for Patients with Early Stage Non-Small Cell Lung Cancer and Osimertinib for Those with EGFR Mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB

B-cell small lymphocytic lymphoma

Not recruiting

Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Breast cancer metastatic+2

Not recruiting

Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Institut Jules Bordet

Myelodysplastic syndrome

Not recruiting

Study of Tamibarotene and Azacitidine Treatment in Newly Diagnosed Adults with RARA-positive Higher-risk Myelodysplastic Syndrome (MDS)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Syros Pharmaceuticals Inc.

Adenocarcinoma gastric

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer After Trastuzumab Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Charleroi

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, particularly in breast cancer, lung cancer, and head and neck cancers. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • HER2-positive breast cancer imaging studies
  • Non-small cell lung cancer therapies
  • Triple-negative breast cancer treatment

Multiple trials investigating personalized medicine approaches and biomarker-driven treatments.

02 Cardiovascular Studies

Research examining treatments for coronary artery disease and post-cardiac arrest care. Trials focus on innovative stent technologies and antiplatelet therapy optimization.

  • Antiplatelet therapy optimization
  • Post-cardiac arrest management
  • Novel stent technologies

Emphasis on improving patient outcomes through targeted interventional approaches.

03 Dermatology and Immunology

Clinical investigations targeting inflammatory skin conditions and immune-mediated disorders. Studies evaluate novel treatments for psoriasis and other dermatological conditions.

  • Plaque psoriasis treatments
  • Prurigo nodularis therapies
  • Severe asthma management

Focus on developing targeted therapies for chronic inflammatory conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.